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Abstract        
The level of evidence to provide treatment recommendations for vestibular schwannoma is 
low compared to other intracranial neoplasms. Therefore, the vestibular schwannoma task 
force of the European Association of Neuro-Oncology assessed the data available in the 
literature and composed a set of recommendations for health care professionals. The 
radiological diagnosis of vestibular schwannoma is made by magnetic resonance imaging. 
Histological verification of the diagnosis is not always required. Current treatment options 
comprise observation, surgical resection, fractionated radiotherapy and radiosurgery. The 
choice of treatment depends on clinical presentation, tumor size and expertise of the treating 
center. In small tumors, observation has to be weighed against radiosurgery, in large tumors 
surgical decompression is mandatory, potentially followed by fractionated radiotherapy or 








This first EANO guideline on the diagnosis, treatment and follow-up of patients with 
vestibular schwannoma (VS) aims at guidance in an area where there is little evidence from 
controlled clinical trials, major variation of clinical practice across sites and countries, but 
urgent need for consensus and standard operating procedures. To facilitate future clinical 
research and to improve overall outcome for patients regarding both functional integrity of 
cranial nerves and long-lasting tumor control, consensus on standard operating procedures is 
demanded. To meet this goal, the European Association of Neuro-Oncology (EANO) 
assembled a task force of experts from various European countries reflecting the 
multidisciplinary approach to this disease to derive recommendations for diagnostic work-up 
and therapy. 
Methods 
The task force represents the clinical disciplines involved in diagnosis and treatment of 
patients with VS and was composed upon suggestions of the EANO board. Specialists 
representing, neurosurgery, ear, nose and throat surgery, radiation oncology, 
pharmacotherapy, neuroradiology, neuropathology, molecular pathology and molecular 
genetics were included. The topics of the guideline were distributed to groups of authors 
according to their clinical profession and scientific profile. The individual authors searched 
the Medline database from January 1990 to July 2018, the Cochrane Library from January 
1990 until July 2018, as well as Embase-Ovid, Cancer Net and Science Citation Index (all 
January 1990 to July 2018). Sensitive and specific keywords as well as combinations of 
keywords were used.  All types of clinical and basic science articles in all languages 
represented by the members of the EANO task force were considered. The main keywords 





outcome, radiosurgery, radiotherapy, schwannoma, sheath, surgery, tumor, vestibular, in 
various combinations.   
In the consensus process with participation of all authors, the literature was evaluated and 174 
papers were chosen for the final guideline. The scientific evidence was rated into classes I-IV 
and recommendations were labeled as level A-C, according to EFNS guidelines1  (see table 
1).When sufficient evidence for recommendations was not available, the task force offered 
advice as "good practice point". 
Clinical presentation and epidemiology  
VS, formerly termed as acoustic neuromas, represent the third most common intracranial non-
malignant tumor entity after meningiomas and pituitary adenomas.1 They are the most 
common extra-axial posterior fossa tumors in adults, comprising over 80% of tumors in the 
cerebellopontine angle.2,3 In most cases the tumors present unilaterally; bilateral VS are a 
hallmark of neurofibromatosis (NF) type 2 (see below).  
Clinically, most patients present with unilateral sensorineural hearing loss (94%) and tinnitus 
(83%). The frequency of the vestibular symptoms vertigo and unsteadiness varies widely 
(17%-75% of patients), but they are likely underreported.4 Large tumors may cause trigeminal 
and facial neuropathies as well as brainstem compression and hydrocephalus.  
According to the Central Brain Tumor Registry of the United States (US) from 2004 to 2010, 
the overall incidence of VS was 1.09 per 100,000/year.5 This incidence increased with age to 
a peak of 2.93 per 100,000/year in the age group 65 – 74 years without gender difference. 
Worldwide there is substantial geographical variation in VS incidence: a recent analysis of the 
Surveillance, Epidemiology, and End Results database in the US including a total of 9,782 VS 
patients among 822 million person-years revealed the median annual disease incidence to be 





VS incidence in Denmark, Sweden, Finland and Norway varies widely by country, with 
highest incidence in Denmark.7 These differences in VS incidence may be due to genetic and 
environmental factors as well as different diagnostic practices. Improved screening protocols 
for asymmetrical hearing loss, better access to advanced imaging and improved resolution of 
magnetic resonance imaging (MRI) have led to an increased number of VS diagnoses and a 
decreased average tumor size at the time of diagnosis.8  
Risk factors for VS have scarcely been investigated. A population-based case-control study of 
VS risk factors in the UK and Nordic countries, revealed an elevated elevated risk for VS in 
parous compared to nulliparous women.9 There was no relation to age at first birth or the 
number of children. Tumor risk was lower in current but not in ex-smokers. The underlying 
biological mechanisms, if any, underlying these observations remain unclear. 
Pathogenesis 
Inactivation of the NF2 tumor suppressor gene is considered a major event in the 
tumorigenesis of conventional schwannoma. A recent whole exome sequencing study 
demonstrated that 77% of VS show evidence of genomic inactivation of NF2 via loss of 
chromosome 22q or NF2 gene mutation.10 NF2 inactivation is the most highly recurrent 
genomic alteration in VS. Bi-allelic inactivation can be demonstrated by exome sequencing in 
45% of cases whereas in 41% of cases only one hit either by heterozygous chromosome 22q 
deletion or NF2 mutation is evident. In 14% of cases no genomic hit in NF2 can be detected 
by exome sequencing. However, the consistent lack of the NF2 gene product merlin in the 
tumor cells of VS suggests that in cases without evidence for genetic inactivation epi-genetic 
mechanisms of NF2 silencing or mutational events in regions not covered by exome 
sequencing likely exist.11 Another recent whole exome sequencing study reports concordant 





studies regarding alterations in non-NF2 genes. While one study found ARID1A (14%), 
ARID1B (18%), DDR1 (11%), TSC1 (9%), TSC2 (7%), CAST (8%), ALPK2 (8%), LZTR1 
(8%) and TAB3 (3%) as additional genes recurrently altered in (vestibular) schwannomas, the 
other study did not find recurrent somatic mutations in these genes but in CDC27 (11%) and 
USP8 (7%).10 Therefore, further studies are required to clarify the role of non-NF2 gene 
mutations in schwannoma pathogenesis. 
RNA-sequencing revealed recurrent SH3PXD2A-HTRA1 fusions on chromosome 10 in about 
10% of VS associated with a male gender predominance and partly co-occurring with genetic 
NF2 inactivation.10 Although the precise biochemical consequences of acquiring this fusion 
remain to be elucidated, activation of the MEK-ERK pathway seems to be involved.  
Bi-allelic inactivation of PRKAR1A by deletion and/or mutation is considered a major event in 
the pathogenesis of melanotic schwannoma.13 In addition, melanotic schwannomas frequently 
show monosomies of chromosomes 1, 2, 17 and 22q as well as variable whole chromosomal 
gains.14,15 
NF 2     
VS are usually solitary tumors, however about 4-6% are associated with NF2, an autosomal 
dominant monogenic condition caused by pathogenic variants in the NF2 gene on 
chromosome 22q.16-18 NF2 has a birth incidence of about 1 in 25,000-33,000 with a diagnostic 
prevalence of around 1 in 60-70,000.16,19 Rarely schwannomatosis caused by pathogenic 
variants in the LZTR1 gene can cause isolated VS or VS that can be misdiagnosed as NF2.20,21  
NF2 can be diagnosed when the criteria in table 2 are fulfilled or when a pathogenic mutation 
in the NF2 gene is found in constitutional DNA or in two anatomically distinct tumors.17,18 
Although NF2 usually presents with bilateral VS, it may present with unilateral VS with other 





also present with apparently isolated VS at young ages, particularly aged <25 years where of 
106 patients with an apparently isolated VS, 9 patients (8.5%) had an NF2 and 3 patients 
(2.9%) had LZTR1 pathogenic variants. First affected individuals in a family and particularly 
those with unilateral presentation are often (30-35%) mosaic for the causative gene variant as 
this occurs during early embryogenesis and was not present in the gamete.21,25 NF2 tumors are 
often multifocal caused by different clonal events and multiple second hits affecting the NF2 
gene in the internal auditory meatus with both roots of the vestibular nerve being affected 
throughout its course in the canal.26,27 This makes surgery and other interventions such as 
radiation treatment more difficult with higher rates of recurrence.28 Radiation should be used 
with caution in young NF2 patients because of the risk malignant transformation and 
secondary tumor induction.28,29 Although NF2 is very variable in its course there are strong 
genotype-phenotype correlations with truncating variants in exons 2-13 associated with 
poorest life expectancy.30 NF2 can cause schwannomas throughout the central and peripheral 
nervous system and patients may also develop meningiomas and spinal ependymomas, the 
associated morbidity affects quality of life severely and reduces life expectancy.29,30 
When to consider NF2? 
NF2 should be considered when an individual presents with a unilateral vestibular or other 
sporadic schwannoma <30 years or meningioma <25 years.21,24,28 Germline pathogenic 
variants can be identified in 1-10% of cases. NF2 should also be considered in older patients 
with two NF2 related tumors although detection rates in germline are low mosaic NF2 can be 
confirmed if an identical NF2 pathogenic variant is found in both tumors.31 
Diagnostic procedures 





Magnetic resonance imaging (MRI) is the method of choice for the identification of suspected 
VS, with contrast-enhanced T1-weighted scans considered to be the gold standard for the 
initial evaluation and postoperative assessment of recurrence or residual tumors.32,33 
Computed Tomography (CT) has a complementary role in the evaluation of VS. It provides 
useful pre-operative information about the surgical anatomy of the skull base, especially the 
petrous bone.34 The MRI protocol should include standard T1-and T2-weighted sequences, 
diffusion-weighted imaging (DWI), and fluid-attenuated inversion recovery sequences 
(FLAIR). DWI imaging is useful to differentiate VS from arachnoid or epidermoid cysts. At 
least one T2-weighted sequence is mandatory to rule out a potential brainstem pathology 
mimicking VS symptoms such as multiple sclerosis or glioma. Axial sub-millimetric heavily 
T2-weighted sequence is the most important sequence in order to evaluate the 
vestibulocochlear nerve and its branches and depict the nerve as a linear hypointense structure 
surrounded by hyperintense CSF within adjacent cisterns (FIESTA, CISS or DRIVE).35 There 
is a general agreement that MRI protocols should include axial T1-weighted sequences before 
and after gadolinium administration. Thin slice spin echo (SE) or TSE/FSE T1-weighted 
sequences or sub-millimetric T1-weighted 3D gradient echo (GRE) sequences can be 
used.34,36  
VS presents as a solid nodular mass with an intracanalicular component in the internal 
acoustic canal (IAC) that often results in its widening. Larger lesions can protrude into the 
cerebellar pontine cistern, whereas smaller lesions are often localized only inside the IAC or 
the labyrinth. The mass is usually isointense on T1-weighted imaging, with strong 
enhancement after gadolinium administration. On T2-weighted imaging, the lesion is 
heterogeneously hyperintense, while larger lesions may show scattered cystic degenerative 





Despite the current debate about omitting the post-gadolinium T1-weighted sequences37,38, 
T1-weighted MRI using gadolinium-based contrast is still considered the gold standard in the 
diagnostic work up of VS.32,33  
Histopathology    
VS, formerly thought to originate from Schwann cells in the glial-Schwannian transitional 
zone of the vestibulocochlear nerve, do in fact arise anywhere along the eighth cranial 
nerve.39 In about 80% of cases they are found in the vestibular portion and in about 20% of 
cases in the cochlear portion.40 The diagnosis is made according to the WHO 2016 
classification.41 The histological picture of conventional VS on hematoxylin/eosin-stained 
sections parallels that of schwannomas in other localizations and is specific enough for a 
morphological diagnosis in the vast majority of cases. Cellular Antoni A areas with 
interlacing bundles of spindle cells alternating with hypocellular, loose microcystic Antoni B 
areas are characteristic. Verocay bodies consisting of arrangements of palisading nuclei 
alternating with zones containing cell processes is another typical architecture of 
schwannomas. Immunohistochemically, VS are diffusely positive for S100B and SOX10. 
Cellular schwannoma and melanotic schwannoma are variants which may raise important 
differential diagnostic considerations. Cellular schwannoma is characterized by 
hypercellularity, predominance or exclusive presence of an Antoni A pattern without (well-
formed) Verocay bodies.42 These tumors are considered benign and therefore the distinction 
from malignant peripheral nerve sheath tumors (MPNST) is important.15,43,44  Melanotic 
schwannoma is recognized by the WHO as a distinct entity that rarely may also affect cranial 
nerves.45-47 Melanotic schwannoma is grossly pigmented and expresses melanocytic markers 
like HMB45 or melan-A, raising a separate differential diagnosis including melanoma. The 
sub-variant of psammomatous melanotic schwannoma has a 50% association with the Carney-





hyperpigmentation and endocrine overactivity.In contrast to conventional or cellular 
schwannoma there is a 10% risk for malignant transformation in melanotic schwannoma.48 
Molecular pathology     
Currently, molecular analyses do not have a role for the diagnosis, prognostication or for 
guiding therapy. Hotspot mutations in GNAQ/GNA11, BRAF and pTERT are helpful for 
differentiating melanotic schwannoma (wild type) from melanocytoma (often GNAQ/GNA11 
mutant) or cutaneous melanoma (often BRAF, pTERT mutant).14,49,50 Epigenetic analyses 
using genome wide methylation profiles emerge as a superb tool for differentiating 
biologically distinct tumor groups. Most VS form a distinctive methylation cluster compared 
to schwannomas from other localizations. Methylation profiles also separate (cellular) 
schwannomas from histological mimics.14,15 A reference set of conventional and melanotic 
schwannomas is included in the recently developed DNA methylation based brain tumor 
classifier tool.51 Additional studies are necessary to clarify whether SH3PXD2A-HTRA1 
fusion or any other molecular alteration in VS is of prognostic relevance. 
Therapeutic strategies 
Observation    
Observing VS with serial MRI scanning and audiological monitoring without any tumor-
directed treatment is considered appropriate for incidental, asymptomatic VS (evidence class 
III, recommendation level C).52 Compliance of patients has to be taken into account, since 
non-compliance could lead to a failure of follow up.53 The task of observational management 
is to monitor tumor growth and hearing function to obtain data for a potential decision for 
therapy. There are hardly any clinical parameters which reliably predict growth in a newly 





tumor location, and even sidedness as predictors of future growth, but these are mostly single 
studies at low evidence levels which were not reproduced.54  The proportion of growing 
tumors at follow-up varies considerably with reported ranges from 30-70% over different 
periods of time, the variation most likely being due to methodological issues.55,56 On average, 
approximately 50% of tumors may be expected to grow over a five-year period.54,57,58 Series 
employing quantitative measurements of VS growth with long term follow up have shown a 
mean maximum diameter growth of 2.9 mm/year (maximum diameter).59 Two recent studies 
found that 50% of patients lost functional hearing during a 3-4 year period.60,61 A full speech 
discrimination score was considered a good predictor for preservation of functional hearing.61  
Four non-randomized studies compared outcomes from observation and stereotactic 
radiosurgery (SRS) showing better tumor control after SRS (evidence class II, 
recommendation level B).53,62-64  Some studies reported less hearing loss in patients with SRS 
whereas in others hearing outcome and complaints were not different.53,62-64 Two studies 
compared either conservative management, surgery or SRS using various quality of life 
questionnaires after 5-7 years of follow-up.65,66 Both reports showed that patients with 
conservative management only, responded more favorably in the questionnaires than those 
who were treated up front. In addition, hearing and facial nerve outcomes were better in 
observed patients; the latter only in comparison with surgery. However, in nearly all observed 
patients the tumors had stayed stable in size, which may represent a relevant bias but also 
indicates the importance of thoughtful indication to treat.  
Surgery        
Surgical management of VS should take into account tumor size and morphology at time of 
diagnosis as well as the patient’s symptoms, comorbidities and preferences.67 There are 
various classification systems for tumor size which support decision making.68-70 Of those, the 





grade IV), surgery is considered as the primary treatment to remove a symptomatic lesion or 
potentially life threatening mass effect.69 Surgery may also be considered for smaller tumors, 
if cystic degeneration is present or if cure is primary goal of treatment      (evidence class IV, 
good practice point).71-73 
The choice of surgical approach depends on hearing status, tumor characteristics, patient’s 
preferences and surgeon’s expertise. The experience of the surgical team is an important 
factor affecting the outcome, suggesting that VS should be treated in high volume centers 
(evidence class IV, good practice point).74-76 Surgery related mortality is 0.5 percent in large 
series.77 The probability of hearing preservation in patients with normal hearing (Gardner 
Robertson class A, see table 4) was >50-75% immediately after surgery, as well as after 2 and 
5 years, and >25 – 50% after 10 years.78,79 Factors influencing preservation of serviceable 
hearing after microsurgery are tumor size < 1 cm, presence of a distal internal auditory canal 
CSF fluid fundal cap as well as good preoperative hearing function. 78  The risk of persisting 
facial palsy is between 3% and 46%.80,81 It depends on tumor size and the occurrence of an 
immediate paresis.80 To improve the rate of functional preservation, intraoperative monitoring 
is mandatory for surgery of VS and should include somatosensoric evoked potentials and 
electromyographic monitoring of the facial nerve comprising direct electrical stimulation and 
free-running electromyography (EMG) (evidence class III, recommendation level B). Facial 
motor evoked potentials are currently being evaluated.74,82 Intraoperative facial nerve 
monitoring leads to improved functional outcome and can be used to accurately predict 
favorable facial nerve function after surgery.74 Brainstem auditory evoked responses should 
also be used when hearing preservation is attempted (evidence class III, recommendation 
level B).78,83,84 In case of large lesions, EMG of the lower cranial nerves is recommended 
(evidence class IV, good practice point). 
Goal of surgery should be the total or near-total resection, since residual tumor volume 





116 patients with VS that were treated by gross total resection (GTR), near total resection 
(NTR) or subtotal resection (STR) yielded recurrence rates of 3.8%, 9.4% and 27.6% 
respectively.85 The mean time to recurrence was 22 months, ranging from 6 to 143 months. In 
a recent study of 103 sporadic VS who underwent NTR or STR, patients with STR 
experienced recurrences over 13 times more often than those treated with NTR.86 In a 
retrospective study with 111 incomplete excisions (NTR and STR), the 7 patients who 
showed evidence of tumor regrowth had all undergone STR.87 Several further series also 
showed a considerably greater risk of regrowth with increasing residual tumor volumes.88-90 
For large VS, the lower risk of recurrence after gross total resection should be weighed 
against the higher risk for facial nerve dysfunction and lower rates of hearing preservation, 
since there seem to be a relationship between tumor volume and functional outcome.91,92  
 
For these cases, partial resection followed by stereotactic radiosurgery (SRS, see below) has 
become increasingly popular.93-96 With this combined approach, the results reported so far 
show superior outcome regarding facial nerve function and hearing preservation when 
compared to total resection, with comparable tumor control rates. However the studies still are 
small and retrospective (evidence class IV, good practice point).93,96 After intentional near 
total or subtotal resection, a watch and scan policy is warranted as only a minority of 
remnants do progress, however the risk increases with the size of the remnant.96 In cases of 
recurrences after radiosurgery, both reoperation and radiosurgical retreatment are possible. 
However, the functional risk for the facial nerve upon surgery is higher after previous 
irradiation and a very meticulous, conservative dissection technique might be necessary 
(evidence class IV, good practice point). In VS recurring after surgery, radiosurgery may be 
used preferentially because the risk of damage to the facial nerve is lower than with a second 






The following approaches are commonly used: 
The suboccipital retrosigmoid (retromastoid) approach is favored by neurosurgeons and is 
particularly indicated for tumors located primarily in the cerebellopontine cistern or tumors 
with significant mass effect. It allows removal of tumors of various sizes and offers the 
possibility of hearing preservation. It provides excellent visualization of the brainstem, cranial 
nerves and relevant vascular structures, but requires some cerebellar retraction and allows 
only limited access to the fundus of the internal auditory canal.101,102 The procedure can be 
performed with the patient in either a (semi-)sitting or a horizontal positioning. Although 
there are some small retrospective studies reporting on superior functional outcome associated 
with the semisitting position, current data does not support favoring a particular positioning 
technique (class IV, good practice point).103-105 
The translabyrinthine approach, usually performed by ENT surgeons, can be used to remove 
tumors of all sizes. A labyrinthectomy will result in complete loss of function of the inner ear 
and is therefore not suitable for patients seeking hearing preservation. The approach provides 
access to the internal auditory canal after labyrithectomy and exposure of the facial nerve 
within the Fallopian canal. The approach has the advantage of excellent tumor access without 
the need of occipital or temporal lobe retraction.106 It offers superior visualization of the entire 
facial nerve from brain stem to its entry into the labyrinthine portion of the Fallopian canal.107 
The middle fossa approach may be considered for patients with small tumors, who would like 
to preserve residual hearing. Suitable access requires temporal craniotomy above the zygoma 
and dissection of dura up to the arcuate eminence.  
This approach requires careful patient selection. Tumor extending to the fundus and extending 
below the transverse crest is more difficult to remove than tumors where there is a CSF cap 
filling the lateral end of the IAC.108,109 Endoscope assisted resection has been reported as an 





smaller tumors and optimal tumor size is less than 1 cm intracranial tumor diameter.112  This 
approach has the potential disadvantage of increased facial nerve manipulation because of the 
anterosuperior course of the facial nerve through the internal auditory canal especially for 
those tumors that arise from the inferior vestibular nerve.113  
 
Altogether, there are no sufficient data supporting the superiority of any approach in terms of 
radical tumor resection and nerve function preservation.114 Therefore, no recommendation can 
be made and the approach should be chosen upon the experience of the treating center. 
Radiosurgery and Radiotherapy  
Stereotactic radiosurgery (SRS) defines delivery of high dose irradiation with high conformity 
and precision in a single fraction and is commonly used for small to medium sized VS. SRS 
can be performed using a Cobalt-60 based  GammaKnife or linear accelerator techniques like 
the CyberKnife using doses from 11 to 14 Gray (Gy).81,115-117 The definition of a 
hypofractionated schedules of up to five fractions as “radiosurgery” remains controversial in 
Europe. In case of larger tumors, fractionation is mandatory. For these cases, fractionated 
radiotherapy (RT) or hypofractionated stereotactic radiotherapy (SRT) using up to 10 
fractions are increasingly used. There are no data providing an outcome based comparison of 
GammaKnife or linear accelerator techniques.52 
Five prospective studies without randomization (evidence class II) have revealed that SRS is 
superior to microsurgery for patients with VS <3 cm in terms of preserving facial nerve and 
hearing function.81,116,118-120 As upper limit for radiosurgery a mass effect on the brainstem 
(Koos IV) is considered, there is no clear definition by diameter or volume alone (evidence 






Several retrospective cohort studies evaluated SRS using GammaKnife with at least 100 
patients, 2 years follow up and objective audiometric assessment. One linear accelerator series 
with over 100 patients included and 2 years follow up did not report functional hearing 
outcome.115 Pioneer series of SRS included patients treated with very high dose regimens. 
Contemporary SRS series using GammaKnife with tumor marginal doses between 12 and 14 
Gy revealed 5-year tumor control rates of 90-99%, hearing preservation rates of 41-79%, 
facial nerve preservation rates of 95-100% and trigeminal preservation rates of 79-99%. 
Numerous authors have found that the key predictor for functional hearing preservation is the 
quality of hearing at time of radiosurgery.121-126 A recent review revealed a relevant decline in 
hearing after SRS, even in patients with normal hearing function (Gardner Robertson grade 
1).78 The probability to preserve hearing was >75-100% after two years, >50-75% after five 
years and >25 -50% after 10 years. After 5 and 10 years, the rates of hearing preservation 
were similar to patients having microsurgery.78 However, it has to be considered that the latter 
data are based on selected surgical cases with a special attempt to preserve hearing. 
The maximum dose at the modiolus of the cochlea has been reported to be a negative 
predictor for functional hearing preservation with a threshold around 4 Gy.122,123,127-130 
However, these series comprise small retrospective cohorts of patients. Cochlear dose is likely 
to be one of many variables associated with hearing preservation. The recommendation is to 
use SRS with a dose of 11-14 Gy at the margin and 11-12 Gy when the risk of hearing loss is 
a critical issue (evidence class III, recommendation level C).52  
There are no randomized, prospective studies comparing SRS and SRT. Six non-
randomized studies found that the functional hearing preservation is similar but the rate of 
facial palsy and trigeminal nerve dysfunction seems higher with SRT than SRS.131-138  
There is little data about the incidence of malignant VS after radiation of spontaneous, 





study using the Surveillance Epidemiology and End Results (SEER) database. The incidence 
of malignant peripheral nerve sheath tumors (MPNST) of the eighth cranial nerve with no 
history of prior radiation was 0.017 per 1 million persons/year. When compared with the 
incidence of benign VS, 1041 VSs were present for every 1 MPNST arising from the eighth 
cranial nerve. There is no evidence that spontaneous MPNST is a feature of NF2  as opposed 
to NF1, nonetheless around half of MPNST reported after radiation treatment are in NF2 
patients.139 This baseline rate of malignancy should be considered when estimating the risk of 
malignant transformation following stereotactic radiosurgery for VS.140 In a retrospective 
single center review, Pollock et al did not find any radiation-induced tumors in 11,264 
patient-years of follow-up after SRS.141 In a review by Maducdoc et al. only eight cases with 
malignant transformation after surgery or SRS were found, four of these patients had surgery 
only.142  
Numerous studies have reported about transient enlargement of VS occurring within 3 
years after radiosurgery.143-147 This MR change observed in up to 30% of the patients is 
related to the therapeutic effect of SRS and is termed pseudoprogression. It is not a predictor 
of failure.143-147 We recommend clinical and radiological observation within this time frame 
performing annual MRI scans (expert opinion, good practice point). 
Systemic treatment options  
Local therapies are the mainstay for the treatment of VS. There is no level I evidence of for 
any systemic treatment and even level II evidence for the treatment with the anti-vascular 
endothelial growth factor antibody bevacizumab is disputable and only valid for 
schwannomas arising in patients with NF 2. In the sequence of therapies, a safe surgical 
resection and radiotherapy are considered as superior. Thus, systemic, medical treatment 
options have been generally used in locally pretreated patients, potentially limiting efficacy 





Bevacizumab has been successfully used for patients with progressive VS associated with 
NF2.148 Patients experienced an improvement of hearing and objective (>20% reduced tumor 
volume) radiographic responses.149 In NF 2 patients with progressive VS a prospective, multi-
institutional, uncontrolled phase II study with 14 patients using 7.5 mg/kg bevacizumab 
administered every 3 weeks revealed a hearing improvement in 36% of patients, and no 
patient with a hearing decline in the trial period of 12 months.150 Volumetric assessments 
demonstrated a partial radiographic response of volume reduction of 20% or more in 43% 
(6/14 patients) making bevacizumab a potential treatment option for NF2 patients (evidence 
class II, recommendation level B).  
 
Other pathways have been addressed based on preclinical or immunohistochemical target 
expression .151 Again, patients studied had VS in the context of NF2. Neither epidermal 
growth factor receptor (EGFR) pathway inhibition using erlotinib nor ErbB2 (and EGFR) 
pathway blockade applying lapatinib has been associated with relevant radiographic responses 
or impact on the hearing function.152,153 The mechanistic target of rapamycin (mTOR) 
signaling cascade has also been proposed for the treatment of NF2 related tumors since the 
mTOR pathway is considered a key driver of tumor growth in merlin (NF2)-deficient tumors. 
Similarly, a small (n=10 patients), single-institution trial study of the mTOR complex 1 
inhibitor everolimus was not associated with tumor shrinkage or hearing improvement.154  
Supportive Care     
There are almost no data about the value of supportive care in VS patients. Therefore, only 
expert opinion based recommendations are possible (good practice point).  
Care should focus on clinical symptoms and treatment complications. Trigeminal and facial 





VS as well as treatment complications. Patients with facial nerve palsy can have various types 
of ocular complications like lagophthalmus, which can lead to exposure keratopathy, corneal 
breakdown, ulcers, and even perforation. Patient management should be based on the severity 
of the ocular findings and ranges from symptomatic treatment like moistening eye drops to 
surgical reanimation of the facial nerve via hypoglossal facial nerve anastomosis and 
symptomatic plastic measure for the eye or face.155-158 Patients with facial nerve palsy who 
present at earlier stages can benefit from conservative treatment. Therapy with corticosteroids 
is frequently administered in this case, however, evidence for this treatment is lacking. 
Decreased hearing can be supported by various hearing aid. We refer the reader to specific 
reviews about multidisciplinary treatment and rehabilitation of facial palsy and lower cranial 
nerve deficits as possible complications of surgical therapy.159-161 
Quality of life   
Tumor size seems to be a predictor for quality of life (QoL) in VS patients.65,162,163 
Several retrospective studies addressed the question, which treatment modality provides the 
best QoL but led to inconsistent results. Observation, resection, radiosurgery and radiotherapy 
were compared using different study designs.65,116,162,164-169 Although there are significant 
discrepancies between these studies, it might be concluded that QoL in patients with VS 
cannot be predicted based on management strategy alone. As expected, poor QoL is more 
likely in patients with large, symptomatic tumors that were resected.65,162,163  
Monitoring and Follow up 
Follow up after treatment as well as with conservative management requires a program of 
MRI scanning, audiometry and outpatient consultation. There are plenty of retrospective data 





data focusing on control intervals are rare. We support annual MRI follow up for five years in 
patients with untreated tumors, thereafter the follow up intervals can be prolonged.33 There 
are also recommendations for a size dependent follow up with a recommendation of six 
month intervals in large tumors.169 In a prospective collection of 196 patients, no onset of 
growth was found in intracanalicular tumors which were stable for five years after 
diagnosis.57 In another large prospectively followed cohort of extra-and intracanalicular 
tumors, 7.2 % exhibited growth after a stable period of five years following diagnosis.170 
Thus, even if the likelihood of growth declines with time, imaging albeit at larger intervals is 
recommended for untreated tumors. 
Based on these data, we recommend annual follow up intervals with MRT and audiometry in 
patients with conservatively treated, radiated and incompletely resected VS for five years. In 
case of stable tumor size, the intervals can be doubled thereafter (recommendation level: good 
practice point). In patients with gross total tumor resection, MRI controls postoperatively and 
after 2, 5 and 10 years are sufficient (expert opinion, recommendation level good practice 
point).  
Specific recommendations: 
VS in general: 
Many tumors are managed in single departments or institutions offering one particular 
treatment. Since there are several therapeutic options possible, especially in medium sized 
tumors, we recommend discussion of patients with VS in multidisciplinary tumor boards. 
Besides treatment decisions, follow up including pseudoprogression can be evaluated by 
specialists from all disciplines involved (expert opinion, good practice point). 
If surgery is indicated, surgical treatment at a high volume center is recommended, since 







Sporadic unilateral VS 
- Small asymptomatic tumor (Koos I-II) 
Management of sporadic, non-NF2 related unilateral VS should depend on symptoms and 
signs, and on the size of the tumor. In small, asymptomatic tumor with regular cranial nerve 
function, observation is the management of choice. The data available provide evidence level 
III and recommendation level C.  
As an alternative to observation, SRS can be performed to stop tumor growth and preserve 
long term nerve function. However, there still is a small risk of deterioration of nerve function 
or QoL. There is evidence level II and recommendation level B for SRS in asymptomatic 
patients.  
If long term preservation of nerve function is the primary aim of management, even surgery 
can be chosen; however, the risk of any functional deterioration is considerable ranging up to 
50 percent (evidence class III). Therefore, we recommend not to perform surgery in these 
patients (recommendation level C). 
- Small tumor with impaired hearing (Koos I-II) 
If patients with small tumors became symptomatic with vestibular and /or auditory symptoms, 
therapy should be discussed to avoid further deterioration. In these cases, SRS offers a better 







- Small tumor with complete hearing loss (Koos I-II) 
In these patients, aim of therapy can be cure or tumor control while preserving facial nerve 
function. All options can be justified in these cases. Observation is usually the first option, 
since there is no function endangered for a long period of time (evidence class III, 
recommendation level C). SRS or surgery carry a low risk of facial nerve damage and may 
provide long term control or cure, respectively. Besides facial nerve function, SRS carries a 
lower risk profile than surgery making SRS the first option, if tumor control is regarded 
sufficient by the patient (evidence class II; recommendation level B).  
- Medium sized tumors (Koos III-IV, < 3 cm) 
Most patients with medium-sized tumors present with vestibular or cochlear symptoms. Facial 
paresis is rare and might even be a hint for a facial schwannoma. Due to the symptomatic 
burden and considerable tumor volume, therapy should be performed. Surgery or radiosurgery 
can be recommended at a very similar level (recommendation level C). The risk profile of 
SRS is lower than of surgery, however, surgery can offer complete removal of the tumor. 
Altogether, this situation should be meticulously discussed with the patients and all options 
explained. Also subtotal resection to preserve function might be an option, if subsequent SRS 
of a growing tumor rest can be provided (good practice point). 
- Large tumor with brain stem compression (Koos IV > 3 cm) 
These patients typically suffer from 8th cranial nerve symptoms for a long time. A 
considerable number of these patients present with additional symptoms like facial nerve 
paresis or gait ataxia. Primary goal of therapy is decompressing the brain stem and stretched 
cranial nerves, what makes surgery the only option. Since there are no prospective studies for 
this clinical situation, recommendation level is good practice point. Surgery in large tumors is 





reason, tumor mass reduction by incomplete resection, followed by SRS or observation is a 
valid option (evidence class IV, good practice point).  
NF2 with uni- or bilateral VS 
Patients with NF2 suffer from bilateral VS or unilateral VS and other intracranial and/or 
spinal tumors (see table 1). The high incidence of newly developing tumors, the fast tumor 
growth and early tumor regrowth as well as the lack of a cure makes patient management 
challenging.171 Generally, observation and follow up should use shorter intervals compared to 
spontaneous VS particularly in younger patients. Follow up intervals of 6-12 months are 
recommended (evidence level IV, recommendation level good practice point). In most 
patients, several consecutive therapies have to be performed to preserve cranial nerve and 
brain stem function. Bilateral VS may lead to intense brain stem compression making surgical 
decompression mandatory. If incomplete resection is performed to preserve 7th and/or 8th 
cranial nerve function, residual tumors may be treated by SRS, in small tumor rests 
observation may be appropriate. In inevitable recurrent situations, therapy depends on the 
clinical condition of the patient, cranial nerve symptoms, tumor size, and therapies performed 
earlier. Re-surgery and re-SRS commonly need to be performed depending on the respective 
risk profile (good practice point). Prospective data show positive effects of bevacizumab on 
hearing and tumor growth (evidence class II), making bevacizumab a good treatment option 
(recommendation level B).172-174 Due to impaired hearing function, auditory rehabilitation is 
of upmost importance for these patients. There are no prospective data on general 
management, surgery or SRS especially for NF2 patients, allowing only recommendation as 
good practice points. 






This guideline presents the recommendations derived from the current state of the literature. 
To generate progress in the area of VS management, we recommend to focus on the following 
issues: 
The value of surgery versus SRS is difficult to evaluate in a prospective manner. 
Randomization is conceivable only in medium and small sized tumors and we suspect that 
patients will be reluctant to undergo randomization. An improved multidisciplinary 
communication in tumor boards might help to solve this problem. 
Since considerable late effects on hearing have been encountered, more information about the 
long time effects of SRS is needed by extending clinical and radiological follow up in VS 
patients more than 10 years. 
According to other putative benign intracranial tumors like meningiomas, molecular profiling 
of VS should be intended on a broad scientific basis (i) to learn more about the reasons for 
clinically different growth behavior within a distinct WHO grade I tumor entity and (ii) to 
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Figure Captions: 
Figure 1 – Intracanalicular and cisternal VS (Koos III). Axial 3D heavily T2-weighted 
sequence (DRIVE) (a) shows a VS expanding from the internal porus acusticus into the 
cerebellopontine-angle cistern. Coronal T2-weighted image (b) depicts slight mass effect on 
middle cerebellar peduncle. Cystic degenerative changes seen on T2 are well evident on axial 
(c) and coronal (d) T1- weighted images after Gadolinium (arrows). 
 
 
 
